The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

Treatment with a spinal cord stimulation system reduced pain and restored sensory nerve function in a small cohort of ...

Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) ...